Previous 10 | Next 10 |
DESTINY-Lung02 Phase II trial shows clinically meaningful efficacy and favorable safety at 5.4mg/kg vs. 6.4mg/kg dose of AstraZeneca and Daiichi Sankyo’s ENHERTU in HER2-mutant disease Updated results from DESTINY-Lung01 Phase II trial demonstrate continued durabl...
Exploratory analysis from POSEIDON Phase III trial also showed trends for overall survival benefit with a limited course of tremelimumab added to IMFINZI and chemotherapy in subgroups with high unmet need Updated results after approximately four years of follow-up of the...
Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease ...
Summary The passing of the Queen has swiftly circled the globe. Now, King Charles holds the torch and has significant power over economies, especially if more hands on than his mother. Interestingly, an initiative already lays out some of the King's favorite holdings and offer...
The pharmaceutical industry is fraught with risk and also filled with opportunity. On one hand, the average new drug took many years of clinical research and cost approximately $1 billion to bring to market between 2009 and 2018. However, a portion of drugs that are able to receive FDA ...
AstraZeneca ( NASDAQ: AZN ) and Merck's ( NYSE: MRK ) Lynparza showed clinically meaningful survival benefit as first line therapy in certain patients with ovarian cancer as per long-term data from two phase 3 trials. AstraZeneca presented 5-year follow-up data f...
Landmark 5-year follow-up of PAOLA-1 Phase III trial demonstrated LYNPARZA plus bevacizumab meaningfully extended survival with 65.5% of HRD-positive patients surviving 5 years vs. 48.4% treated with bevacizumab and placebo SOLO-1 Phase III trial demonstrated 67%...
Do you have $5,000 that you can afford to invest, but you aren't sure which stocks to buy? A couple of no-brainer stocks that make for ideal buy-and-forget investments are AstraZeneca (NASDAQ: AZN) and Microsoft (NASDAQ: MSFT) . They are leaders in their respective industrie...
Summary Merck delivers a great quarter led by their blockbuster Keytruda as well as other oncology and vaccine recovery. As a seller of one of the U.S.' largest blockbusters, there are some regulatory risks on Keytruda. Thankfully, they are quite limited in the medium term. Pa...
Summary AstraZeneca’s stock dipped 5.8% in August, the biggest monthly fall in 2022, raising the question whether it is a good time to buy the otherwise high-performing stock on dip. Factors like relatively better performance by healthcare stocks in the current sluggish eco...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC Company Name:
AZN Stock Symbol:
NYSE Market:
First BTK inhibitor to show favorable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in comb...
The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate...
New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Socie...